Dipeptidyl peptidase-4 inhibitors: 3 years of experience

Diabetes Technology and Therapeutics

Volumn 14, Issue 4, 2012, Pages 350-364

  Derosa, Giuseppe ^a   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; METFORMIN PLUS SITAGLIPTIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

ABDOMINAL PAIN; ADD ON THERAPY; COMMON COLD; DIABETES MELLITUS; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; LIVER DYSFUNCTION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SKIN MANIFESTATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION;

ADAMANTANE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; NITRILES; PURINES; PYRROLIDINES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84859341109     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0204     Document Type: Review

References (64)

1. American Diabetes Association. Standards of medical care in diabetes 2011. Diabetes Care 2011;34(Suppl 1):S11-S61 .
2. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000;342:381-389. Erratum in: N Engl J Med 2000;342:1376.
3. Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, Stevens MJ, Feldman EL; DCCT/EDIC Research Group: Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006;29:340-344. (Pubitemid 44106515)
4. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
5. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572. (Pubitemid 351831357)
6. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559. (Pubitemid 351831356)
7. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes: Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203.
8. Groop L: Sulfonylureas in NIDDM. Diabetes Care 1992;15: 737-747.
9. Malaisse WJ: Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol 2003;2:401-414. (Pubitemid 37462239)
10. Krentz AJ, Bailey CJ: Oral antidiabetic agents. Current role in type 2 diabetes mellitus. Drugs 2005;65:385-411. (Pubitemid 40227460)
11. Barnett AH: Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vasc Health Risk Manage 2009;5:141-151.
12. Derosa G, Tinelli C, Maffioli P: Effects of pioglitazone and rosiglitazone combined with metformin on body weight in people with diabetes. Diabetes Obes Metab 2009;11:1091-1099.
13. Tourrel C, Bailbé D, Meile MJ, Kergoat M, Portha B: Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001;50:1562-1570.
14. Hui H, Nourparvar A, Zhao X, Perfetti R: Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A-and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003;144:1444-1455. (Pubitemid 36432086)
15. Perfetti R, Zhou J, Doyle ME, Egan JM: Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000;141:4600-4605. (Pubitemid 32055138)
16. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80:952-957.
17. Triplitt CL: New technologies and therapies in the management of diabetes. Am J Manag Care 2007;13(Suppl 2):547-554.
18. Triplitt C, McGill JB, Porte D Jr, Conner CS: The changing landscape of type 2 diabetes: The role of incretin-based therapies in managed care outcomes. J Manag Care Pharm 2007;13(9 Suppl C):S2-S16.
19. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF: Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther 2010;12:233-240.
20. Derosa G, Putignano P, Bossi AC, Bonaventura A, Querci F, Franzetti IG, Guazzini B, Testori G, Fogari E, Maffioli P: Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur J Pharmacol 2011;666:251-256.
21. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF: Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 2010;59:887-895.
22. Derosa G, Maffioli P, Ferrari I, Mereu R, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Salvadeo SA: Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. Horm Metab Res 2010;42: 663-669.
23. Derosa G, Maffioli P: Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 2011;4:263-271.
24. Dickersin K, Scherer R, Lefebvre C: Identifying relevant studies for systematic reviews. BMJ 1994;309:1286-1291. (Pubitemid 24340510)
25. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of randomized controlled trials: is blinding necessary? Control Clin Trials 1996;17:1-12. (Pubitemid 26120810)
26. Herman GA, Bergman A, Liu F, Stevens C, Wang AQ, Zeng W, Chen L, Snyder K, Hilliard D, Tanen M, Tanaka W, Meehan AG, Lasseter K, Dilzer S, Blum R, Wagner JA: Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006;46:876-886. (Pubitemid 44050824)
27. Mentlein R: Dipeptidyl-peptidase IV (CD26) role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24. (Pubitemid 29505281)
28. El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D, Nauck MA: The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab 2007;92:4165-4171. (Pubitemid 350074727)
29. Onglyza [package insert]. Princeton, NJ: Bristol-Myers Squibb Company/Wilmington, DE: AstraZeneca Pharmaceuticals, 2011.
30. Tradjenta (linagliptin) tablets. Highlights of prescribing information. Initial U.S. Approval: 2011. Boehringer Ingelheim International GmbH. bidocs.boehringer-ingelheim .com/BIWebAccess/ViewServlet.ser?docBase = renetnt& folderPath=/Prescribing+Information/PIs/Tradjenta/Tradjenta .pdf (last accessed July 2011).
31. clinicaltrials.gov/ct2/show/NCT00968708 (last accessed January 23, 2012).
32. Dipeptidyl peptidase-4 inhibitors ('gliptins') for type 2 diabetes mellitus. NPS RADAR. www.nps.org.au/health-professionals/publications/nps-radar/ 2008/august-2008/gliptins (last accessed August 6, 2010).
33. Masur K, Schwartz F, Entschladen F, Niggemann B, Zaenker KS: DPPIV inhibitors extend GLP-2 mediated tumour promoting effects on intestinal cancer cells. Regul Pept 2006;137:147-155. (Pubitemid 44841989)
34. Aschner P, Katzeff HL, Guo H, Sunga S, Williams-Herman D, Kaufman KD, Goldstein BJ; Sitagliptin Study 049 Group: Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:252-261.
35. Reasner C, Olansky L, Seck TL, Williams-Herman DE, Chen M, Terranella L, Johnson-Levonas AO, Kaufman KD, Goldstein BJ: The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011;13:644-652.
36. Yoon KH, Shockey GR, Teng R, Golm GT, Thakkar PR, Meehan AG, Williams-Herman DE, Kaufman KD, Amatruda JM, Steinberg H: Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of b-cell function in patients with type 2 diabetes. Int J Clin Pract 201;65:154-164.
37. Arechavaleta R, Seck T, Chen Y, Krobot KJ, O'Neill EA, Duran L, Kaufman KD, Williams-Herman D, Goldstein BJ: Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011;13:160-168.
38. Seck T, Nauck M, Sheng D, Sunga S, Davies MJ, Stein PP, Kaufman KD, Amatruda JM; Sitagliptin Study 024 Group: Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: A 2-year study. Int J Clin Pract 2010;64:562-576.
39. Vilsbll T, Rosenstock J, Yki-Järvinen H, Cefalu WT, Chen Y, Luo E, Musser B, Andryuk PJ, Ling Y, Kaufman KD, Amatruda JM, Engel SS, Katz L: Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:167-177.
40. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Sndergaard RE, Davies M; 1860-LIRA-DPP-4 Study Group: Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375: 1447-1456.
41. Kikuchi M, Haneda M, Koya D, Tobe K, Onishi Y, Couturier A, Mimori N, Inaba Y, Goodman M: Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus. Diabetes Res Clin Pract 2010;89:216-223.
42. Matthews DR, Dejager S, Ahren B, Fonseca V, Ferrannini E, Couturier A, Foley JE, Zinman B: Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010;12:780-789.
43. Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, Shao Q, Dejager S: Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11:157-166.
44. Foley JE, Sreenan S: Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes. Horm Metab Res 2009;41:905-909.
45. Filozof C, Gautier JF: A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: A 52-week, randomized study. Diabet Med 2010;27:318-326.
46. Filozof C, Schwartz S, Foley JE: Effect of vildagliptin as addon therapy to a low-dose metformin. World J Diabetes 2010;1:19-26.
47. Blonde L, Dagogo-Jack S, Banerji MA, Pratley RE, Marcellari A, Braceras R, Purkayastha D, Baron M: Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial a primary care, type 2 diabetes study. Diabetes Obes Metab 2009;11:978-986.
48. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A: Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: A 24-week, double-blind, randomized trial. Diabetes Care 2007;30:217-223. (Pubitemid 46198322)
49. Pfutzner A, Paz-Pacheco E, Allen E, Frederich R, Chen R; CV181039 Investigators: Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab 2011;13:567-576.
50. Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R; CV181-039 Investigators: Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial. Diabetes Obes Metab 2009;11:611-622.
51. DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, Chen RS; Saxagliptin 014 Study Group: The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-1655.
52. Goke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I; D1680C00001 Investigators: Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: A 52-week randomised controlled trial. Int J Clin Pract 2010;64:1619-1631.
53. Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, Woerle HJ: Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:65-74.
54. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA: Effect of linagliptin monotherapy on glycaemic control and markers of b-cell function in patients with inadequately controlled type 2 diabetes: A randomized controlled trial. Diabetes Obes Metab 2011;13:258-267.
55. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA: Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13:653-661.
56. Owens DR, Swallow R, Dugi KA, Woerle HJ: Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: A 24-week randomized study. Diabet Med 2011;28:1352-1361.
57. Marfella R, Barbieri M, Grella R, Rizzo MR, Nicoletti GF, Paolisso G: Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations. J Diabetes Complications 2010;24:79-83.
58. Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I: Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010;26:540-549.
59. Ahrén B: Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab 2009;23:487-498.
60. Cryer PE. Hypoglycemia, Pathophysiology, Diagnosis and Treatment. New York: Oxford University Press, 1997.
61. Laing SP, Swerdlow AJ, Slater SD, Botha JL, Burden AC, Waugh NR, Smith AW, Hill RD, Bingley PJ, Patterson CC, Qiao Z, Keen H: The British Diabetic Association Cohort Study. II: Cause-specific mortality in patients with insulintreated diabetes mellitus. Diabet Med 1999;16:466-719.
62. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE, Kengne AP, Marre M, Heller S; ADVANCE Collaborative Group: Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010;363:1410-1418.
63. Barzilai N, Guo H, Mahoney EM, Caporossi S, Golm GT, Langdon RB, Williams-Herman D, Kaufman KD, Amatruda JM, Goldstein BJ, Steinberg H: Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011;27:1049-1058.
64. Schweizer A, Dejager S, Foley JE, Shao Q, Kothny W: Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population 75 years: A pooled analysis from a database of clinical trials. Diabetes Obes Metab 2011;13:55-64.